Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCXW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicus Pharma Ltd. SEC filings document material-event reporting for a clinical-stage life sciences and biotechnology company incorporated in Ontario. The filings identify the company's one-segment operating model and record capital-structure activity involving common shares, shelf registration statements, at-the-market offering arrangements and a standby equity purchase agreement.
Recent Form 8-K disclosures also cover unregistered equity sales, debenture financing with subsidiary guaranties, debt repayment mechanics, amendments to equity distribution agreements and listing-compliance notices. These filings frame the company's financing arrangements, governance obligations, securities registration activity and exchange-status disclosures.
Medicus Pharma Ltd. director Raju Ajay received a stock option grant for 25,000 common shares. The award gives him the right to buy 25,000 shares at an exercise price of $0.50 per share. The option becomes exercisable on March 26, 2027 and expires on March 27, 2031, and his directly held option position reported in this filing totals 25,000 derivative securities.
Medicus Pharma Ltd. reported that Chief Medical Officer Mehmud Faisal received a grant of stock options as part of his compensation. The award covers 125,000 stock options, each exercisable for one common share at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this award, Faisal holds 125,000 stock options directly.
Medicus Pharma Ltd. director May Sara R. received a grant of stock options covering 25,000 underlying common shares. The options have an exercise price of $0.50 per share and can first be exercised on March 26, 2027.
These options expire on March 27, 2031. Following this grant, May Sara R. holds derivative securities representing 25,000 common shares, reflecting a compensation-related award rather than an open-market purchase.
Medicus Pharma Ltd. director Patrick J. Mahaffy received a compensation-related stock option grant, not an open-market trade. He was granted options to acquire 25,000 common shares at an exercise price of $0.50 per share. These options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031. Following this grant, he holds options for 25,000 shares directly.
Medicus Pharma Ltd. director Larry Kaiser received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and are scheduled to expire on March 27, 2031. Following this award, he holds 25,000 derivative securities linked to Common Shares.
Medicus Pharma Ltd. director Robert J. Ciaruffoli reported receiving a grant of stock options covering 25,000 underlying Common Shares. The options have a conversion price of $0.50 per share, are exercisable beginning on March 26, 2027, and expire on March 27, 2031. Following this award, he holds 25,000 stock options directly.
Medicus Pharma Ltd. Chief Scientific Officer Brennan Edward J. received a grant of stock options, giving him the right to acquire 25,000 Common Shares. The options have an exercise price of $0.50 per share and expire on March 27, 2031. Following this award, he holds 25,000 options directly.
Medicus Pharma Ltd. reported that President and CFO Carolyn F. Bonner received a grant of stock options as equity compensation. She was awarded options for 100,000 Common Shares at an exercise price of $0.50 per share, giving her the right to buy shares at that price in the future.
The options become exercisable on March 26, 2027 and expire on March 27, 2031. Following this grant, Bonner holds stock options covering 100,000 shares. This is an acquisition of derivative securities, not an open‑market purchase or sale of the company’s stock.
Medicus Pharma Ltd. Chief Executive Officer Raza Bokhari received a grant of stock options for 325,000 Common Shares. The options have an exercise price of $0.50 per share and were awarded at no cost on the grant date.
The options become exercisable on March 26, 2027 and are scheduled to expire on March 27, 2031 if not exercised. Following this grant, Bokhari holds stock options covering a total of 325,000 underlying Common Shares directly as reported in this filing.
Medicus Pharma Ltd. director Ashton William received a grant of stock options, giving him the right to acquire 25,000 common shares. The options have an exercise price of $0.50 per share and expire in 2031. Following this compensation award, he holds options covering 25,000 shares directly.